Clinical Trial Update: Pembrolizumab in HNSCC With Residual Disease After Radiation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab for head and neck squamous cell carcinoma with residual disease after radiation was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Yale University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-11-18